Summary
Thermo Fisher Scientific Inc. announced on October 17, 2023, that it has entered into a Purchase Agreement with Olink Holding AB (publ) to commence a tender offer for all outstanding common shares and American Depositary Shares of Olink. This strategic move signifies Thermo Fisher's intent to acquire Olink, a company specializing in advanced protein biomarker detection. Investors should note that the tender offer has not yet commenced, and the announcement serves as informational, not an offer to purchase. The acquisition, if successful, is expected to expand Thermo Fisher's capabilities in life sciences research and diagnostics. The filing also includes standard forward-looking statements and details on where investors can find additional information regarding the tender offer as it progresses through regulatory filings. The deal is subject to customary closing conditions and regulatory approvals.
Key Highlights
- 1Thermo Fisher Scientific (TMO) is launching a tender offer to acquire Olink Holding AB (publ).
- 2The offer will be for all outstanding common shares and American Depositary Shares of Olink.
- 3A definitive Purchase Agreement has been executed between Thermo Fisher and Olink.
- 4The tender offer has not yet officially commenced.
- 5The acquisition aims to enhance Thermo Fisher's presence in protein biomarker detection and life sciences.
- 6Further details and official offer documents will be filed with the SEC.
- 7Investors are advised to review all tender offer materials once available for definitive terms and conditions.